ContraFect Corporation (NASDAQ:CFRX) Files An 8-K Other Events

ContraFect Corporation (NASDAQ:CFRX) Files An 8-K Other Events
Item 8.01 Other Information.

Exebacase development update

ContraFect Corporation (the “Company”) has supported an investigator initiated study of exebacase in a study of arthroscopic debridement and implant retention (“DAIR”) with local administration of exebacase (lysin CF-301) in elderly patients for relapsing multidrug-resistant Staphylococcal prosthetic knee infection. The Company believes exebacase has the potential to be used as salvage therapy during arthroscopic DAIR in patients with relapsing Staphylococcal prosthetic joint infection to improve the efficacy of suppressive antibiotics and to avoid considerable loss of function. The Company expects to continue this study in the first quarter of 2020.

The Company has filed an application with Biomedical Advanced Research and Development Authority (BARDA) under its Broad Agency Announcement BAA-18-100-SOL-00003 Amendment 10, dated October 15, 2019, to develop exebacase and additional portfolio programs as non-traditional antibacterial therapeutics that treat or prevent resistant infections. The Company may be able to advance the application to the subsequent stage of the process by the second quarter of 2020.

Gram-negative lysin program update

The Company believes it will be able to select an IND candidate, targeting Pseudomonas aeruginosa, from its gram-negative lysin program to initiate IND-enabling activities to progress the product candidate to an IND filing. The potential therapeutic indication(s) will be determined as clinical development progresses.

CF-296 program update

As previously disclosed, the Company has engineered a lysin variant of exebacase which it believes may suitable for the potential treatment of the most challenging invasive infections caused by Staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The Company recently began IND-enabling activities to progress CF-296 to an IND filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1    Contrafect Pipeline Chart

Story continues below


CONTRAFECT Corp Exhibit
EX-99.1 2 d811366dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   ContraFect Pipeline Program Pathogen Discovery Preclinical Phase 1 Phase 2 Phase 3 Bacteremia,…
To view the full exhibit click here

An ad to help with our costs